BrainChild Bio spins out of Seattle Children's to develop ...
Seattle Children's Hospital launched BrainChild Bio, a biotech startup focusing on CAR-T cell therapies for pediatric brain tumors, leveraging technology and funding from the hospital. With prior clinical testing and plans for future trials, BrainChild aims for accelerated approval, despite FDA scrutiny into CAR-T therapy's safety risks.
Reference News
Seattle Children's Hospital launched BrainChild Bio, a biotech startup focusing on CAR-T cell therapies for pediatric brain tumors, leveraging technology and funding from the hospital. With prior clinical testing and plans for future trials, BrainChild aims for accelerated approval, despite FDA scrutiny into CAR-T therapy's safety risks.
Seattle Children's Hospital launches BrainChild Bio, a biotech startup focusing on CAR-T cell therapies for pediatric brain tumors, leveraging technology and funding from the hospital. With prior clinical testing and plans for future trials, BrainChild aims for accelerated approval, despite FDA scrutiny over CAR-T therapy's safety risks.